Australia markets closed

Alpha Teknova, Inc. (TKNO)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
1.28000.0000 (0.00%)
At close: 04:00PM EDT
1.2916 +0.01 (+0.91%)
After hours: 05:54PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close1.2800
Open1.3500
Bid0.9288 x 200
Ask1.6000 x 200
Day's range1.2300 - 1.3000
52-week range1.1550 - 4.2700
Volume169,804
Avg. volume30,263
Market cap52.254M
Beta (5Y monthly)0.33
PE ratio (TTM)N/A
EPS (TTM)-1.0500
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.50
  • GlobeNewswire

    Teknova Announces Closing of $15.4 Million Private Placement

    HOLLISTER, Calif., July 12, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced the closing of its previously announced private placement for the issuance and sale of an aggregate of 12,385,883 shares of its common stock at a purchase price of $1.24 per share. The private placement was priced based on the Nasda

  • GlobeNewswire

    Teknova Announces $15.4 Million Private Placement

    HOLLISTER, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate 12,385,883 of its shares of common stock in a private placement at a purchase price of $1.24 per share. The private placement was priced based

  • GlobeNewswire

    Teknova Provides Strategic Business Update and Announces Preliminary Second Quarter 2024 Results

    Second quarter 2024 total revenue is in the range of $9.4 to $9.6 million Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today provided a business update including preliminary unaudited financial results for the second q